Literature DB >> 33095414

Prostaglandin A1 Decreases the Phosphorylation of Tau by Activating Protein Phosphatase 2A via a Michael Addition Mechanism at Cysteine 377.

Guo-Biao Xu1,2, Pei-Pei Guan1, Pu Wang3.   

Abstract

Prostaglandin (PG) A1 is a metabolic product of cyclooxygenase 2 (COX-2) that is potentially involved in regulating the development and progression of Alzheimer's disease (AD). PGA1 is a cyclopentenone (cy) PG characterized by the presence of a chemically reactive α,β-unsaturated carbonyl. PGA1 is potentially involved in the regulation of multiple biological processes via Michael addition; however, the specific roles of PGA1 in AD remain unclear. TauP301S transgenic (Tg) mice were used as in vivo AD models, and neuroblastoma (N) 2a cells were used as an in vitro neuronal model. The PGA1-binding proteins were identified by HPLC-MS-MS after intracerebroventricular injection (i.c.v) of PGA1. Western blotting was used to determine tau phosphorylation in PGA1-treated Tg mice in the absence or in the presence of okadaic acid (OA), an inhibitor of protein phosphatase (PP) 2A. A combination of pull-down assay, immunoprecipitation, western blotting, and HPLC-MS-MS was used to determine that the PP2A scaffold subunit A alpha (PPP2R1A) is activated by the direct binding of PGA1 to cysteine 377. The effect of inhibiting tau hyperphosphorylation was tested in the Morris maze to determine the inhibitory effects of PGA1 on cognitive decline in tauP301S Tg mice. Incubation with N2a cells, pull-down assay, and mass spectrometry (MS) analysis revealed and indicated that PGA1 binds to more than 1000 proteins; some of these proteins are associated with AD and especially with tauopathies. Moreover, short-term administration of PGA1 in tauP301S Tg mice significantly decreased tau phosphorylation at Thr181, Ser202, and Ser404 in a dose-dependent manner. This effect was caused by the activation of PPP2R1A in tauP301S Tg mice. Importantly, PGA1 can form a Michael adduct with cysteine 377 of PPP2R1A, which is critical for the enzymatic activity of PP2A. Long-term treatment of tauP301S Tg mice with PGA1 activated PP2A and significantly reduced tau phosphorylation resulting in improvements in cognitive decline in tauP301S Tg mice. Our data provided new insight into the mechanisms of the ameliorating effects of PGA1 on cognitive decline in tauP301S Tg mice by activating PP2A via a mechanism involving the formation of a Michael adduct with cysteine 377 of PPP2R1A.

Entities:  

Keywords:  Alzheimer’s disease; Michael addition; Prostaglandin A1; Protein phosphatase 2A scaffold subunit A alpha; Tau

Year:  2020        PMID: 33095414     DOI: 10.1007/s12035-020-02174-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  70 in total

Review 1.  Cholesterol in Alzheimer's disease.

Authors:  Leila A Shobab; Ging-Yuek R Hsiung; Howard H Feldman
Journal:  Lancet Neurol       Date:  2005-12       Impact factor: 44.182

Review 2.  Integrated communications between cyclooxygenase-2 and Alzheimer's disease.

Authors:  Pei-Pei Guan; Pu Wang
Journal:  FASEB J       Date:  2018-07-18       Impact factor: 5.191

3.  Cyclooxygenase-2 Induced the β-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-Δ12,14-prostaglandin J2.

Authors:  Pei-Pei Guan; Yun-Yue Liang; Long-Long Cao; Xin Yu; Pu Wang
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

4.  Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice.

Authors:  Jing-Wen Guo; Pei-Pei Guan; Wei-Yan Ding; Si-Ling Wang; Xue-Shi Huang; Zhan-You Wang; Pu Wang
Journal:  Biomaterials       Date:  2017-07-14       Impact factor: 12.479

Review 5.  Genomics of Alzheimer Disease: A Review.

Authors:  Roger N Rosenberg; Doris Lambracht-Washington; Gang Yu; Weiming Xia
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

6.  Membrane permeation induced by aggregates of human islet amyloid polypeptides.

Authors:  Chetan Poojari; Dequan Xiao; Victor S Batista; Birgit Strodel
Journal:  Biophys J       Date:  2013-11-19       Impact factor: 4.033

7.  Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes.

Authors:  Narkunaraja Shanmugam; Irene T Gaw Gonzalo; Rama Natarajan
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

8.  Prostaglandin I2 upregulates the expression of anterior pharynx-defective-1α and anterior pharynx-defective-1β in amyloid precursor protein/presenilin 1 transgenic mice.

Authors:  Pu Wang; Pei-Pei Guan; Jing-Wen Guo; Long-Long Cao; Guo-Biao Xu; Xin Yu; Yue Wang; Zhan-You Wang
Journal:  Aging Cell       Date:  2016-05-30       Impact factor: 9.304

9.  Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1β and Aβ between glial and neuron cells.

Authors:  Pu Wang; Pei-Pei Guan; Tao Wang; Xin Yu; Jian-Jun Guo; Zhan-You Wang
Journal:  Aging Cell       Date:  2014-03-13       Impact factor: 9.304

10.  Transferrin is responsible for mediating the effects of iron ions on the regulation of anterior pharynx-defective-1α/β and Presenilin 1 expression via PGE2 and PGD2 at the early stage of Alzheimer's Disease.

Authors:  Chen-Di Lu; Ji-Kang Ma; Zheng-Yang Luo; Qun-Xi Tai; Pu Wang; Pei-Pei Guan
Journal:  Aging (Albany NY)       Date:  2018-11-01       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.